Cantor Fitzgerald Comments on Arcellx FY2025 Earnings

Key Points

• Cantor Fitzgerald projects Arcellx's FY2025 earnings per share at ($2.98), significantly lower than the current consensus estimate of ($1.58) per share.
• The company's stock is receiving positive attention from numerous analysts, with a consensus rating of "Buy" and an average target price of $114.31.
• Insider transactions show that Director Kavita Patel sold shares for a total of $101,040, while hedge funds collectively own 96.03% of Arcellx's stock.

Arcellx, Inc. (NASDAQ:ACLX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Arcellx in a note issued to investors on Monday, August 4th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will earn ($2.98) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Arcellx's current full-year earnings is ($1.58) per share. Cantor Fitzgerald also issued estimates for Arcellx's FY2026 earnings at ($2.65) EPS.

Arcellx (NASDAQ:ACLX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.94) EPS for the quarter, beating analysts' consensus estimates of ($1.03) by $0.09. Arcellx had a negative net margin of 329.93% and a negative return on equity of 41.63%. The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $16.76 million.

A number of other brokerages have also issued reports on ACLX. Scotiabank increased their target price on shares of Arcellx from $93.00 to $133.00 and gave the stock a "sector outperform" rating in a research report on Thursday, July 31st. HC Wainwright restated a "buy" rating and set a $115.00 target price on shares of Arcellx in a research report on Monday, June 16th. Finally, Citigroup began coverage on shares of Arcellx in a research report on Tuesday, June 17th. They set a "buy" rating and a $110.00 target price on the stock. Thirteen analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $114.31.

Arcellx Stock Performance

ACLX traded down $0.65 on Wednesday, reaching $70.50. The company had a trading volume of 867,672 shares, compared to its average volume of 446,817. Arcellx has a fifty-two week low of $47.86 and a fifty-two week high of $107.37. The stock has a market cap of $3.89 billion, a P/E ratio of -20.61 and a beta of 0.28. The company's fifty day moving average is $67.52 and its 200 day moving average is $65.20.

Insider Buying and Selling

In related news, Director Kavita Patel sold 1,500 shares of the stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $67.36, for a total value of $101,040.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 8.35% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arcellx

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACLX. GAMMA Investing LLC lifted its stake in Arcellx by 104.1% in the 1st quarter. GAMMA Investing LLC now owns 494 shares of the company's stock valued at $32,000 after purchasing an additional 252 shares during the last quarter. Headlands Technologies LLC bought a new position in Arcellx in the 4th quarter valued at approximately $41,000. PNC Financial Services Group Inc. lifted its stake in Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company's stock valued at $49,000 after purchasing an additional 486 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in Arcellx in the 1st quarter valued at approximately $50,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Arcellx during the fourth quarter valued at $87,000. Institutional investors own 96.03% of the company's stock.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).